GlassScriptPhysician profile
Matthew D Lippas
NPI 1790770717
$1,067.46
in general payments reported to CMS, 2019-2025
16 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $82.70 · 2021: $89.55 · 2022: $166 · 2023: $207 · 2024: $49.95 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.79 | 2023-2025 | |
| Notal Vision, INC. | $141.90 | 2022 | |
| Sun Pharmaceutical Industries INC. | $122.99 | 2019-2023 | Cequa |
| Allergan, INC. | $84.08 | 2020-2021 | |
| Glaukos Corporation | $80.75 | 2019-2025 | Idosetr |
| Astellas Pharma US INC | $66.10 | 2025 | Izervay |
| Genentech USA, INC. | $50.12 | 2022-2023 | Vabysmo |
| Alcon Vision LLC | $39.99 | 2020 | |
| Rxsight INC | $36.41 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Aerie Pharmaceuticals, INC. | $32.64 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $30.83 | 2024 | Xdemvy |
| Dompe US, INC. | $27.06 | 2025 | Oxervate |
| Biotissue Holdings INC. | $24.45 | 2023 | |
| Apellis Pharmaceuticals, INC. | $24.42 | 2023 | Syfovre |
| Lkc Technologies, INC. | $20.45 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $18.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lippas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.